In cancers with advanced malignant transformation, increased expression of TGF-β strongly induces cancer cell proliferation [18], and TGF-β is known to be associated with proliferation in prostate cancer [19], suggesting that the growth of prostate cancer cell lines was inhibited by nanaomycin K. Other studies have reported that the relative fold change after 72 h of treatment with Olaparib in PC-3 was 5.1 [20]. Here, TGFB1 is linked to prostate cancer.